Archive for the ‘Indiana spinoffs’ Category

Biotechnology Firm ImmuneWorks (Indiana) Begins National Clinical Trial for New Idiopathic Pulmonary Fibrosis (IPF) Treatment (10/19/2010)

November 1, 2010

Immuneworks was founded by Indiana University School of Medicine researchers to develop and commercialize treatments for serious autoimmune lung diseases.

ImmuneWorks, Inc. today announced the initiation of its Phase I clinical trial to evaluate the safety, tolerability, and biologic effects of three doses of IW001 in patients suffering from idiopathic pulmonary fibrosis (IPF), a serious lung disease. The clinical trial will move the biotech company one step closer to commercialization of its lead IPF treatment compound. read more